Project: Life changing therapy for Osteo-Arthritis patients: a biomarker lead approach.
| Acronym | OA_BIO (Reference Number: 114932) |
| Duration | 01/05/2021 - 01/05/2024 |
| Project Topic | We will complete pre- and early clinical development (Phase I) of 4P-004, a first-in-class disease-modifying drug for osteoarthritis (OA). 4P-004 is a new formulation of Liraglutide and a breakthrough therapy for OA with a unique triple effect: anti-inflammation, anti-pain and cartilage regeneration. A strong scientific partnership will enable 4P-004 efficacy measurement and patient stratification in later clinical testing, OA imaging and liquid biopsy biomarkers will also be validated. |
| Network | Eurostars 2 |
| Call | Eurostars Cut–off 14 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 1 | 4Moving Biotech | Coordinator | France |
| 2 | AO Research Institute Davos | Partner | Switzerland |
| 3 | Chondrometrics GmbH – medical data processing | Partner | Germany |
| 4 | Utrecht University | Partner | Netherlands |